T
199800
vs
K
KOSPI 200
Over the past 12 months, ToolGen Inc has underperformed KOSPI 200, delivering a return of 0% compared to KOSPI 200's +150% growth.
Stocks Performance
199800 vs KOSPI 200
Performance Gap
199800 vs KOSPI 200
Performance By Year
199800 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
ToolGen Inc
Glance View
ToolGen Inc. is a South Korean biotechnology company best known for gene-editing technology based on CRISPR/Cas9. It develops genome-editing tools and related research materials that let scientists cut and modify DNA in cells. The company also works on therapeutic and agricultural applications built around that core technology. Its customers are mainly pharmaceutical and biotech companies, research institutes, and other organizations that need gene-editing technology for R&D. ToolGen makes money by selling research tools, offering technology licenses, and entering partnerships that let others use its intellectual property in their own products and programs. What makes ToolGen’s business different is that it sits upstream in the gene-editing value chain. Instead of selling finished medicines, it supplies the core editing technology and the rights to use it, which means its business is tied to scientific adoption, licensing deals, and the spread of gene-editing across drug development and life-science research.
